8-K: enGene Reports Strong 2025 Results, Advances Bladder Cancer Therapy

enGene Holdings Inc. announced full year 2025 financial results and significant progress in its pivotal LEGEND trial for high-risk bladder cancer, extending its cash runway into 2H 2028.

Summary

• Completed enrollment of 125 patients in the pivotal cohort of the LEGEND trial for high-risk, BCG-unresponsive NMIBC with carcinoma in situ, exceeding the target by 25%.
• Reported preliminary 6-month complete response rate of 62% in pivotal cohort patients enrolled under the amended LEGEND protocol.
• Selected for the FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program.
• Planned Biologic License Application (BLA) submission for detalimogene in the second half of 2026, with potential approval in 2027.
• Cash, cash equivalents, and marketable securities totaled $202.3 million as of October 31, 2025.
• Successfully closed an underwritten public offering in November, raising $140.1 million in net proceeds.
• Combined cash and proceeds are expected to provide a cash runway into the second half of 2028.
• Full year 2025 total operating expenses increased to $123.2 million from $62.3 million in 2024.
• Net loss attributable to common shareholders for 2025 was $117.3 million, or $2.29 per share, compared to $55.1 million, or $1.46 per share, in 2024.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data, successful over-enrollment in a pivotal trial, significant capital raise extending the cash runway, and key regulatory designations (RMAT, Fast Track, CDRP). While operating expenses and net loss increased, this is expected for a clinical-stage biotech advancing a pivotal program towards BLA submission. The overall outlook is highly positive for the company's strategic objectives.

Positives

• Completed enrollment in the LEGEND pivotal cohort with 125 patients, exceeding the target by 25%.
• Reported a preliminary 6-month complete response rate of 62% in pivotal cohort patients, supporting detalimogene's competitive profile.
• Selected for the FDA's CDRP Program, facilitating CMC development and promoting earlier engagement with the FDA.
• Successfully closed a public offering in November, raising $140.1 million in net proceeds.
• Extended cash runway into the second half of 2028, providing financial stability for ongoing development.
• Appointed Hussein Sweiti, M.D., MSc, as Chief Medical Officer, bringing significant oncology and regulatory experience.
• Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA.

Negatives

• Total operating expenses increased significantly to $123.2 million for the full year 2025, up from $62.3 million in 2024.
• Research and development expenses increased by $56.2 million, primarily due to manufacturing, personnel, and clinical costs for the LEGEND trial and BLA preparation.
• General and administrative expenses increased by $4.7 million due to scaling public company operations.
• Net loss attributable to common shareholders increased to $117.3 million ($2.29 per share) in 2025, from $55.1 million ($1.46 per share) in 2024.

Risks

• No guarantee that detalimogene will successfully complete necessary clinical development phases, including achieving positive results in the pivotal cohort of the LEGEND study.
• No guarantee that clinical trial results or feedback from regulatory authorities will ultimately lead to Biologics License Application (BLA) submission for, and the approval of, detalimogene.
• Management's expectations and forward-looking statements could be affected by numerous important factors, risks, and uncertainties beyond enGene's control.
• Preliminary clinical data may not predict the final results of the trial.
• Changes in the results from enGene's clinical trials could occur due to new data, subsequent analysis of existing data, and audit and verification procedures.
• The content and timing of decisions made by the FDA and other regulatory authorities may impact development and approval timelines.
• Risks related to the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites, and enroll patients in its clinical trials.
• Challenges in executing on the Company's clinical development plans and securing regulatory approval on anticipated timelines.

Future Outlook

The company anticipates providing a data update on the LEGEND trial's pivotal cohort in the second half of 2026, following discussions with the FDA and accumulation of sufficient 12-month complete response data. A Biologics License Application (BLA) filing for detalimogene's pivotal cohort is planned for the second half of 2026, with a potential approval targeted for 2027. The company expects its current cash position, combined with recent financing, to fund operations into the second half of 2028.

Management Comments

• "We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved."
• "With recent acceptance into FDAs CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in preparation for our planned BLA filing in the second half of 2026 and a potential approval in 2027."
• "The Company continues to believe that detalimogenes emerging profile supports its potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)."

Industry Context

This announcement positions enGene as a significant player in the non-muscle invasive bladder cancer (NMIBC) treatment landscape, particularly for BCG-unresponsive patients who face high recurrence rates and limited options. The development of detalimogene, a non-viral gene therapy, represents a potential advancement over existing treatments, including the standard Bacillus Calmette-Gurin (BCG) therapy. The FDA's Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, along with participation in the CDRP program, highlight the recognized unmet medical need and the potential for accelerated development and review of such therapies in oncology. The appointment of a Chief Medical Officer with prior experience in J&J's bladder cancer portfolio and FDA approvals further strengthens the company's strategic focus in this competitive therapeutic area.

Comparison to Industry Standards

• The preliminary 6-month complete response rate of 62% for detalimogene in BCG-unresponsive NMIBC with CIS is a key metric. For context, other approved therapies in this space, such as Merck's KEYTRUDA (pembrolizumab), showed a 40.6% complete response rate at 12 months in its pivotal trial for BCG-unresponsive NMIBC with CIS. UroGen Pharma's Jelmyto (mitomycin) for high-risk upper tract urothelial cancer (UTUC) showed a 58% complete response rate at 3 months. While direct comparisons are complex due to different patient populations and trial designs, enGene's preliminary 62% at 6 months appears competitive and promising for a first-line therapy in this challenging indication.
• The tolerability profile, with 42% treatment-related adverse events, 1.6% dose interruptions, and 0.8% dose discontinuations, suggests a generally favorable safety profile, which is crucial for patient adherence and quality of life compared to more invasive or systemic treatments.
• The FDA's CDRP program selection, RMAT, and Fast Track designations indicate regulatory recognition of detalimogene's potential to address a high unmet medical need, aligning with industry efforts to expedite therapies for serious conditions.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, and clear path towards BLA submission and potential approval, which could increase shareholder value.
• Patients: Potential for a new, effective, and well-tolerated treatment option for high-risk, BCG-unresponsive NMIBC, addressing a significant unmet medical need.
• Employees: Growth and scaling of the organization in preparation for commercialization, potentially leading to new opportunities and job security.
• Regulatory Authorities: Increased collaboration with the FDA through the CDRP program, facilitating CMC development and potentially accelerating patient access to the therapy.

Next Steps

• Provide a data update on the LEGEND trial's pivotal cohort in the second half of 2026, following discussion with the FDA on its statistical analysis plan and accumulation of sufficient 12-month CR data points.
• Planned Biologics License Application (BLA) filing for LEGEND's pivotal cohort in the second half of 2026.
• Scaling the organization in preparation for the planned BLA filing and potential approval in 2027.
• Continue evaluating detalimogene in additional LEGEND cohorts (2a, 2b, 3).

Key Dates

Recommendation

The company has achieved significant milestones, including completing enrollment in its pivotal trial with promising preliminary 6-month complete response data (62%), which appears competitive in a high-unmet-need indication. The successful capital raise of $140.1 million extends the cash runway into 2H 2028, de-risking the financial aspect of development. Furthermore, FDA designations (RMAT, Fast Track, CDRP) underscore the regulatory support and potential for expedited review. The planned BLA filing in 2H 2026 and potential approval in 2027 provide a clear timeline for value inflection. While operating expenses and net loss increased, this is typical for a biotech advancing a late-stage asset and is supported by the extended cash runway. The overall progress and outlook suggest strong potential for future growth and market penetration.

Keywords

enGene Holdings Inc., ENGN, Biotechnology, Gene Therapy, Non-Muscle Invasive Bladder Cancer, NMIBC, BCG-unresponsive, Carcinoma in situ, CIS, Detalimogene Voraplasmid, LEGEND trial, Clinical Trial Results, FDA, CDRP Program, BLA Submission, Financial Results, Cash Runway, Public Offering, Oncology, Drug Development